Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2100043772Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: pathological complete response rate. Started Mar 2021; status: recruiting.
02
Drugs
tislelizumabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100043772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043772.